Navigation Links
Breakthrough research identifies how cells from pigs may cure diabetes
Date:9/22/2007

MINNEAPOLIS, Minn. Within three years, insulin-producing islet cells from pigs may be used in clinical trials on a path to finally cure insulin dependant diabetes.

This key finding was the discovery of Dr. Bernhard Hering, Scientific Director of the Diabetes Institute for Immunology & Transplantation at the University of Minnesota and his team, who documented their medical breakthrough in the prestigious scientific journal Nature Medicine in March of 2006.

On Thursday, September 20, at 10:00 a.m. CDT, Hering will present the latest research on pig islet xenotransplantation at the Diabetes Research and Wellness Foundation Symposium at the Hyatt Regency Minneapolis in Minneapolis, MN.

The symposium will be part of The Transplantation Societys 2007 Joint Conference (www.cts-ipita-ixa-2007.org), an international event that will unite the greatest innovators from three sections of the Transplantation Society the Cell Transplant Society (CTS), the International Pancreas and Islet Transplant Association (IPITA) and the International Xenotransplantation Association (IXA) for the first time in history. Hering also serves as the Joint Conference president.

Research has shown that the transplantation of islet cells, harvested from the pancreas of a pig, yields a long-term reversal of diabetes in monkeys, opening the path to unprecedented new opportunities for human patients with the disease. To oversee immunosuppression issues, researchers are now working to transplant porcine islets in an engineered pre-vascularized, cytoprotective and immune-privileged implantation site. This procedure has a number of advantages including:

  • Pigs will be able to provide unlimited islet tissue in a few years.

  • Pig islets from young disease-free donors are superior to cadaver human islets.

  • The actual risk of infectious disease transmission is lower with xenotransplantation of islets.

  • Bioengineering of islet implantation sites into a pre-vascularized, cytoprotective and immune-privileged site will allow for local and selective immunosuppression.

  • Promoting long-term survival of the porcine islet xenografts in humans.

As Hering and his team prepare to enter into clinical trials slated to commence within three years Spring Point Project (www.springpointproject.org), a non-profit organization, is helping to grow a population of medical grade pigs so that once the cure is realized, diabetes sufferers will find the treatment to be widely available and affordable.

Dr. Henk-Jan Schuurman, CEO of Spring Point Project, will moderate the Source Pigs for Xenotransplantation Trials Symposium on Saturday, September 15 at the Hyatt Regency Minneapolis, during the Joint Conference.

In order to have high health pigs available for clinical trials, Spring Point Project now operates a 21,000-square-foot biosecure facility in Western Wisconsin called the Diabetes Research and Wellness Foundation Islet Resource Facility. Inside, a team of highly skilled veterinarians and animal care staff is actively raising high health pigs in compliance with governmental regulations a charge that requires the pigs to be housed in an ultra clean biosecure environment, fed special food and given only purified water to drink and filtered air to breathe.

Continuing to populate our Islet Resource Facility brings us closer to meeting our ultimate goal of curing diabetes, Schuurman says. With the pigs that are currently housed in our biosecure facility, were already expediting the widespread availability of islet cell tissue so that an adequate supply of pig donors will be available for clinical islet cell transplantation trials using patients with diabetes.


'/>"/>

Contact: Molly Kersten
mkersten@r-p.com
419-241-2221
R/P Marketing Public Relations
Source:Eurekalert

Related biology technology :

1. Stem cell breakthrough by UW shows why federal research should be broadened
2. Madison-based Mithridion seeks to capitalize on Alzheimers breakthrough
3. Biotech Pioneer Discusses Breakthrough in Osteoporosis Treatment
4. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
5. Quantitation of the Protein MIA as a Marker for Chondrocytes in Research Samples
6. Control Your siRNA Research
7. Getting Started with MicroRNA Research
8. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
9. Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C
10. Research Organics
11. A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche ... with peritoneal or pleural mesothelioma. Their findings are the subject of a new article ... Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):